Alsop J, Flewett TH, Foster JR. "Hand-foot-and-mouth disease" in Birmingham in 1959. Br Med J. 1960;2:1708-1711.
Ishimaru Y, Nakano S, Yamaoka K, et al. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55:583-588.
Dolin R. Hand-foot-and-mouth disease. In: Freedberg I, ed. Fitzpatrick's dermatology in general medicine. 6th ed. New York, NY: McGraw-Hill; 2003:2049-2052.
Weston WL, Lane AT, Morelli JG. Color textbook of pediatric dermatology. 3rd ed. St Louis, MO: Mosby Inc.; 2002:108-109.
Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291:222-227.
Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;18:1092-1096.
Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024-2032.
1. Robinson CR, Doane FW, Rhodes AJ. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can Med Assoc J. 1958;79:615-621.
2. Alsop J, Flewett TH, Foster JR. "Hand-foot-and-mouth disease" in Birmingham in 1959. Br Med J. 1960;2:1708-1711.
3. Miller GD, Tindall JP. Hand-foot-and-mouth disease. JAMA. 1968;203:827-830.
4. Chang LY, King CC, Hsu KH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109:e88.
5. Ishimaru Y, Nakano S, Yamaoka K, et al. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55:583-588.
6. Dolin R. Hand-foot-and-mouth disease. In: Freedberg I, ed. Fitzpatrick's dermatology in general medicine. 6th ed. New York, NY: McGraw-Hill; 2003:2049-2052.
7. Weston WL, Lane AT, Morelli JG. Color textbook of pediatric dermatology. 3rd ed. St Louis, MO: Mosby Inc.; 2002:108-109.
8. Krafchik BR, Tellier R. Viral exanthems. In: Harper J, Oranje A, Prose N, eds. Textbook of pediatric dermatology. 2nd ed. Hoboken, NJ: Wiley-Blackwell. 2005:415-416.
9. Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291:222-227.
10. Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007;356:1226-1234.
11. Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;18:1092-1096.
12. Lee TC, Guo HR, Su HJ, et al. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J. 2009;28:904-910.
13. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024-2032.
14. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818-828.
15. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829-837.
16. Tsao KC, Chang PY, Ning HC, et al. Use of molecular assay in diagnosis of hand, foot and mouth disease caused by enterovirus 71 or coxsackievirus A 16. J Virol Methods. 2002;102:9-14.
17. Faulkner CF, Godbolt AM, DeAmbrosis B, et al. Hand, foot and mouth disease in an immunocompromised adult treated with aciclovir. Australas J Dermatol. 2003;44:203-206.
18. Chow KC, Lee CC, Lin TY, et al. Congenital enterovirus 71 infection: a case study with virology and immunohistochemistry. Clin Infect Dis. 2000;31:509-512.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台